Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223476 · ClinicalTrials.gov registry record
Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,926
- Enrollment target
NCT07223476 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,926 participants.
The verdict
NCT07223476 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,926 participants
- Enrollment target
Study Summary
Assess and characterize the real-world cyclin-dependent kinase 4/6 inhibitor (CDKI) use in advanced/metastatic breast cancer (a/mBC), evaluate treatment persistence, and quantify CDKI dose adjustments in Portugal. This study used secondary data from the IQVIA database that collects data from hospital drug consumption. The study included 16 public hospitals across Portugal, for which data on consumption of drugs used in hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) a/mBC treatment was available. Patient selection was based on a set of criteria considering all patients with treatments in the a/mBC setting with use of at least one CDKI from November 2018 to May 2023.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,926 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2024-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223476
The ClinicalTrials.gov registry entry for NCT07223476 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,926 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07223476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07223476 about?
NCT07223476 is a clinical study titled "Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal". Assess and characterize the real-world cyclin-dependent kinase 4/6 inhibitor (CDKI) use in advanced/metastatic breast cancer (a/mBC), evaluate treatment persistence, and quantify CDKI dose adjustments in Portugal. This study used secondary data from the IQVIA database that collects data from hospit...
What is the current status of trial NCT07223476?
This trial is currently completed. The enrollment target is 1,926 participants. The study started on 2024-03-29. Estimated completion is 2024-07-01.
Who is sponsoring clinical trial NCT07223476?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.